Autolus Therapeutics plc (NASDAQ:AUTL) Given Average Rating of “Buy” by Brokerages

Autolus Therapeutics plc (NASDAQ:AUTL) has been given a consensus rating of “Buy” by the six analysts that are covering the company, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $9.52.

Several research analysts have weighed in on AUTL shares. Needham & Company LLC reiterated a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, January 13th. Wells Fargo & Company dropped their target price on shares of Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a report on Friday.

Hedge Funds Weigh In On Autolus Therapeutics

Hedge funds have recently made changes to their positions in the business. Jane Street Group LLC acquired a new position in Autolus Therapeutics during the fourth quarter worth $26,000. Barclays PLC raised its position in Autolus Therapeutics by 1,094.3% during the fourth quarter. Barclays PLC now owns 11,859 shares of the company’s stock worth $28,000 after acquiring an additional 10,866 shares in the last quarter. Dumont & Blake Investment Advisors LLC acquired a new position in shares of Autolus Therapeutics during the 4th quarter worth about $35,000. Arkadios Wealth Advisors bought a new stake in shares of Autolus Therapeutics in the 4th quarter valued at about $47,000. Finally, Capstone Investment Advisors LLC acquired a new stake in Autolus Therapeutics in the 3rd quarter valued at about $51,000. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Trading Up 1.5 %

Shares of NASDAQ:AUTL traded up $0.03 during midday trading on Friday, hitting $1.70. The company had a trading volume of 1,642,224 shares, compared to its average volume of 1,375,171. Autolus Therapeutics has a 12 month low of $1.57 and a 12 month high of $6.60. The firm has a fifty day simple moving average of $2.03 and a 200 day simple moving average of $2.93. The stock has a market cap of $452.36 million, a price-to-earnings ratio of -1.40 and a beta of 2.07.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $2.98 million. Equities analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.